±±¾©Ê¯ÓÍ»¯¹¤Ñ§Ôº2026ÄêÑо¿ÉúÕÐÉú½ÓÊÕµ÷¼Á¹«¸æ
²é¿´: 2482  |  »Ø¸´: 12
µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû

Tina_1988

Í­³æ (³õÈëÎÄ̳)

[ÇóÖú] ÇóÖúÀ´ÄÇÌæÄáÉÏÊÐÐÅÏ¢£¿ ÒÑÓÐ1È˲ÎÓë

ÔÚÍøÉÏ¿´µ½Óй«Ë¾¹ÒÀ´ÄÇÌæÄáÏîÄ¿ºÏ×÷ÐÅÏ¢£¬ÔÚCDEÉÏÓÐÀ´ÄÇÌæÄáÆ¬µÄ½ø¿ÚÉêÇ룬µ«ÊÇÎÒÈ´²é²»µ½¸ÃÒ©µÄ¾ßÌåÉÏÊÐÐÅÏ¢£¬ÌØ´ËÇóÖú£¬Íû´óÏÀÏà°ï£¬Ð»Ð»£¡
»Ø¸´´ËÂ¥

» ÊÕ¼±¾ÌûµÄÌÔÌûר¼­ÍƼö

ò§çïҩѧ

» ²ÂÄãϲ»¶

» ±¾Ö÷ÌâÏà¹Ø¼ÛÖµÌùÍÆ¼ö£¬¶ÔÄúͬÑùÓаïÖú:

ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

Tina_1988

Í­³æ (³õÈëÎÄ̳)

ÒýÓûØÌû:
2Â¥: Originally posted by kdl0721 at 2014-08-27 16:55:56
ÏÖÔÚÓ¦¸ÃÊÇÕýÔÚÉêÇë½ø¿ÚÁÙ´²°É£¬µÈ½ø¿Ú»¹µÃÐèÒª2-3Äê°É¡£

ÄãºÃ£¬Ð»Ð»»Ø¸´¡£ÎÒÏë²é¸ÃÒ©ÔÚ¹úÍâµÄÉÏÊÐÐÅÏ¢£¬Ò»Ö±Ã»ÕÒµ½£¬¡­¡­
3Â¥2014-08-27 16:58:18
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
²é¿´È«²¿ 13 ¸ö»Ø´ð

kdl0721

½ð³æ (ÖøÃûдÊÖ)

¡¾´ð°¸¡¿Ó¦Öú»ØÌû

¡ï ¡ï ¡ï ¡ï ¡ï
¸Ðл²ÎÓ룬ӦÖúÖ¸Êý +1
Tina_1988: ½ð±Ò+5, лл»Ø¸´ 2014-08-28 11:30:26
ÏÖÔÚÓ¦¸ÃÊÇÕýÔÚÉêÇë½ø¿ÚÁÙ´²°É£¬µÈ½ø¿Ú»¹µÃÐèÒª2-3Äê°É¡£
2Â¥2014-08-27 16:55:56
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

kdl0721

½ð³æ (ÖøÃûдÊÖ)

¡¾´ð°¸¡¿Ó¦Öú»ØÌû

ÒýÓûØÌû:
3Â¥: Originally posted by Tina_1988 at 2014-08-27 16:58:18
ÄãºÃ£¬Ð»Ð»»Ø¸´¡£ÎÒÏë²é¸ÃÒ©ÔÚ¹úÍâµÄÉÏÊÐÐÅÏ¢£¬Ò»Ö±Ã»ÕÒµ½£¬¡­¡­...

À´ÄÇÌæÄᣨneratinib£©¸Õ»ñ×öÍê¢óÆÚÁÙ´²ÊÔÑ飨ExteNET£©£¬ÏÖÔÚ»¹Ã»ÉÏÊС£
4Â¥2014-08-28 08:46:35
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

áEÓûÌÕÈ»

ľ³æ (ÕýʽдÊÖ)

Puma Biotechnology, under license from Pfizer (previously Wyeth), is developing neratinib (PB-272; HKI-272), an irreversible pan-HER (Erbb1, ErbB2 and ErbB4) tyrosine kinase inhibitor, for the potential oral treatment of HER2-positive cancers, primarily breast cancer
    In July 2009, worldwide phase III breast cancer trials were initiated by Wyeth in patients who had received prior trastuzumab-based therapy ; in October 2011, following its acquisition of rights, Puma intended to terminate the ongoing Pfizer-sponsored trials , and the company began its own phase III trial in third-line metastatic breast cancer in June 2013 . In July 2014, Puma planned to file the drug for approval in the extended adjuvant setting for breast cancer in 1H15 .

Development in other HER2-positive cancer settings is ongoing. In April 2013, a phase II trial in patients with NSCLC was ongoing . In October 2013, a phase II study in patients with other solid tumors with a HER2 mutation was initiated ; in March 2014, initial data from the trial were expected in 2014
¹²¾ýÒ»×íÒ»ÌÕ
5Â¥2014-08-28 09:04:03
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[¿¼ÑÐ] Çóµ÷¼Á323²ÄÁÏÓ뻯¹¤ +8 1124361 2026-03-24 8/400 2026-03-30 15:11 by topgun2009
[¿¼ÑÐ] 284Çóµ÷¼Á +14 junqihahaha 2026-03-26 15/750 2026-03-30 14:12 by ̽123
[¿¼ÑÐ] 322Çóµ÷¼Á +8 ËÎÃ÷ÐÀ 2026-03-27 8/400 2026-03-30 13:38 by chemdavid
[¿¼ÑÐ] 283Çóµ÷¼Á£¨080500£© +14 A child 2026-03-27 14/700 2026-03-30 12:06 by ̽123
[Óлú½»Á÷] ¿¼Ñе÷¼Á +5 watb 2026-03-26 5/250 2026-03-30 11:51 by yjolah
[¿¼ÑÐ] 085600²ÄÁÏÓ뻯¹¤µ÷¼Á +6 kikiki7 2026-03-30 6/300 2026-03-30 10:57 by ÐÇ¿ÕÐÇÔÂ
[¿¼ÑÐ] 348Çóµ÷¼Á +6 СÀÁ³æ²»ÀÁÁË 2026-03-28 6/300 2026-03-30 10:29 by Evan_Liu
[¿¼ÑÐ] ²ÄÁÏ¿ÆÑ§Ó빤³ÌÇóµ÷¼Á +6 ÉîVËÞÉá°É 2026-03-29 6/300 2026-03-29 20:51 by ÌÆãå¶ù
[¿¼ÑÐ] »·¾³¹¤³Ì 085701£¬267Çóµ÷¼Á +6 minht 2026-03-29 6/300 2026-03-29 16:21 by ѧԱ8dgXkO
[¿¼ÑÐ] 327Çóµ÷¼Á +6 ¼³Òàê» 2026-03-29 6/300 2026-03-29 13:40 by peike
[¿¼ÑÐ] ²ÄÁÏѧ˶333Çóµ÷¼Á +11 ±±µÀÏï 2026-03-24 11/550 2026-03-29 08:31 by fmesaito
[¿¼ÑÐ] 0856Çóµ÷¼Á +13 zhn03 2026-03-25 14/700 2026-03-29 08:13 by fmesaito
[¿¼ÑÐ] 071000ÉúÎïѧÇóµ÷¼Á£¬³õÊԳɼ¨343 +7 ССÌðÃæÍÅ 2026-03-25 7/350 2026-03-28 20:25 by ÌÆãå¶ù
[¿¼ÑÐ] 311£¨085601£©Çóµ÷¼Á +4 liziyeyeye 2026-03-28 4/200 2026-03-28 18:50 by 535743368
[¿¼ÑÐ] 266·Ö£¬Çó²ÄÁÏÒ±½ðÄÜÔ´»¯¹¤µÈµ÷¼Á +7 ÍÛºôºßºôºß 2026-03-27 9/450 2026-03-28 12:22 by zllcz
[¿¼ÑÐ] 081200-314 +3 LILIQQ 2026-03-27 4/200 2026-03-28 09:41 by ±£»¤µØÇòÄãÎÒ×öÆ
[¿¼ÑÐ] 285Çóµ÷¼Á +4 AZMK 2026-03-27 7/350 2026-03-27 20:59 by AZMK
[¿¼ÑÐ] ²ÄÁϵ÷¼Á 5+4 ÏëÒªÒ»ºøÌÒ»¨Ë® 2026-03-25 10/500 2026-03-26 19:56 by ²»³Ôô~µÄ؈
[¿¼ÑÐ] Öйú¿ÆÑ§ÔºÉîÛÚÏȽø¼¼ÊõÑо¿Ôº-¹âÏË´«¸Ð¿ÎÌâ×éÕÐÉú-Öйú¿ÆÑ§Ôº´óѧ¡¢ÉîÛÚÀí¹¤´óѧÁªÅà +5 YangTyu1 2026-03-26 5/250 2026-03-26 18:27 by èßäèßäѽ
[¿¼ÑÐ] »¯Ñ§µ÷¼ÁÒ»Ö¾Ô¸ÉϺ£½»Í¨´óѧ336·Ö-±¾¿ÆÉϺ£211 +4 СÓã°®Óлú 2026-03-25 4/200 2026-03-26 10:19 by aa331100
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û